Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Company Overview - Disc Medicine is a clinical-stage biotechnology company focused on therapies for serious hematologic diseases, leveraging expertise in red blood cell biology and iron homeostasis pathways [7] - The company has a market capitalization of $2.51 billion and employs 142 people [3][4] Recent Transactions - Jean M. Franchi, CFO of Disc Medicine, sold 11,156 shares for approximately $720,000 on February 17 and 18, 2026, which is the largest individual open-market transaction by Franchi to date, accounting for 13.52% of his direct holdings [1][5] - Post-transaction, Franchi holds 71,343 shares valued at approximately $4.6 million [2] Financial Performance - Disc Medicine reported a net loss of $212.18 million for the trailing twelve months (TTM) and has seen a 22.33% price change over the past year [3] - The company’s stock is down approximately 15% in 2026 as of February 28, following the FDA's rejection of its drug bitopertin [8] FDA Approval and Workforce Reduction - The FDA rejected bitopertin due to concerns over trial data and potential abuse, despite the application being submitted through a fast-track review program [9] - Following the FDA rejection, the company announced a 20% workforce reduction and reported a doubling of its net loss for the fiscal year compared to the previous year [10]